Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial ; volume:22 ; number:1 ; day:11 ; month:11 ; year:2020 ; pages:1-14 ; date:12.2020
Breast cancer research ; 22, Heft 1 (11.11.2020), 1-14, 12.2020
- Urheber
-
Quintela-Fandino, Miguel
Holgado, Esther
Manso, Luis
Morales, Serafin
Bermejo, Begoña
Colomer, Ramon
Apala, Juan V.
Blanco, Raquel
Muñoz, Manuel
Caleiras, Eduardo
Iranzo, Vega
Martinez, Mario
Dominguez, Orlando
Hornedo, Javier
Gonzalez-Cortijo, Lucia
Cortes, Javier
Gasol Cudos, Ariadna
Malon, Diego
Lopez-Alonso, Antonio
Moreno-Ortíz, María C.
Mouron, Silvana
Mañes, Santos
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01362-y
- URN
-
urn:nbn:de:101:1-2020122219294576776526
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Quintela-Fandino, Miguel
- Holgado, Esther
- Manso, Luis
- Morales, Serafin
- Bermejo, Begoña
- Colomer, Ramon
- Apala, Juan V.
- Blanco, Raquel
- Muñoz, Manuel
- Caleiras, Eduardo
- Iranzo, Vega
- Martinez, Mario
- Dominguez, Orlando
- Hornedo, Javier
- Gonzalez-Cortijo, Lucia
- Cortes, Javier
- Gasol Cudos, Ariadna
- Malon, Diego
- Lopez-Alonso, Antonio
- Moreno-Ortíz, María C.
- Mouron, Silvana
- Mañes, Santos
- SpringerLink (Online service)
Ähnliche Objekte (12)
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Priming
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Priming
Arzneimittel Profil Durvalumab
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Retinal Vasculitis Secondary to Durvalumab
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine